Propanc Biopharma, Inc.(PPCB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PPCB Propanc Biopharma, Inc.

盘后交易 04-30 18:07:34 EDT

0.1016

+0.0016

+1.60%

盘后0.1022

+0.0006+0.59%

17:52 EDT

最高0.1024	最低0.0975	成交量40.52万
今开0.0975	昨收0.1000	日振幅4.85%
总市值222.09万	流通市值167.73万	总股本2,186万
成交额4.03万	换手率2.45%	流通股本1,651万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PPCB","market":"US","secType":"STK","nameCN":"Propanc Biopharma, Inc.","latestPrice":0.1016,"timestamp":1777579200000,"preClose":0.1,"halted":0,"volume":405200,"hourTrading":{"tag":"盘后","latestPrice":0.1022,"preClose":0.1016,"latestTime":"17:52 EDT","volume":17,"amount":1.7305000400000001,"timestamp":1777585972008,"change":0.0006,"changeRate":0.005906,"amplitude":0.018701},"delay":0,"changeRate":0.015999999999999903,"floatShares":16509280,"shares":21859300,"eps":-13.5424,"marketStatus":"盘后交易","change":0.0016,"latestTime":"04-30 18:07:34 EDT","open":0.097547,"high":0.1024,"low":0.097547,"amount":40308.469392,"amplitude":0.04853,"askPrice":0.105,"askSize":2000,"bidPrice":0.0991,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-13.5424,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1777593600000},"marketStatusCode":4,"adr":0,"listingDate":1743998400000,"exchange":"NASDAQ","adjPreClose":0.1,"preHourTrading":{"tag":"盘前","latestPrice":0.0959,"preClose":0.1,"latestTime":"09:18 EDT","volume":23493,"amount":2279.08999485,"timestamp":1777555131714,"change":-0.0041,"changeRate":-0.041,"amplitude":0.032},"postHourTrading":{"tag":"盘后","latestPrice":0.1022,"preClose":0.1016,"latestTime":"17:52 EDT","volume":17,"amount":1.7305000400000001,"timestamp":1777585972008,"change":0.0006,"changeRate":0.005906,"amplitude":0.018701},"volumeRatio":0.360905},"requestUrl":"/m/hq/s/PPCB/wiki","defaultTab":"wiki","newsList":[{"id":"1118487671","title":"Propanc Biopharma公司提交文件，计划由售股股东转售最多1500万股普通股——SEC备案披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1118487671","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118487671?lang=zh_cn&edition=full","pubTime":"2026-04-11 05:33","pubTimestamp":1775856802,"startTime":"0","endTime":"0","summary":"Propanc Biopharma公司已向美国证券交易委员会提交相关文件，内容涉及一项由售股股东发起的普通股转售计划。根据备案信息，该计划拟转售的普通股数量最高可达1500万股。\n此次提交标志着售股股东可能将在公开市场进行大规模股份出售。相关细节已在SEC备案中列明，市场将密切关注此举对公司股权结构及二级市场股价的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193342077","title":"Propanc Biopharma与西班牙哈恩大学及格拉纳达大学达成多年抗衰老与癌症研究合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1193342077","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193342077?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:46","pubTimestamp":1774356416,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. (OTC PINK: PPCB) 已正式启动与西班牙哈恩大学及格拉纳达大学的长期研究合作。该合作项目聚焦于抗衰老机制与癌症治疗领域的前沿探索，旨在通过多学科交叉研究推动新型生物医药解决方案的开发。此次合作将整合双方在生物医药领域的科研优势，共同探索潜在的新型疗法，为应对全球老龄化挑战及癌症治疗提供新的科学依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169122345","title":"Propanc Biopharma, Inc. 优先推进PRP临床开发，聚焦胰腺癌与卵巢癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1169122345","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169122345?lang=zh_cn&edition=full","pubTime":"2026-03-12 21:07","pubTimestamp":1773320852,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. 正全力推进其核心候选药物PRP的临床开发进程，并将胰腺癌与卵巢癌的治疗研究作为首要战略方向。公司致力于通过创新疗法应对这些高致死率癌症的临床挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142670016","title":"Propanc Biopharma公司PRP药物I B期首次人体试验定于2026年启动；1亿美元资金设施已就位","url":"https://stock-news.laohu8.com/highlight/detail?id=1142670016","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142670016?lang=zh_cn&edition=full","pubTime":"2026-03-12 21:06","pubTimestamp":1773320789,"startTime":"0","endTime":"0","summary":"生物制药公司Propanc Biopharma Inc宣布，其主打候选药物PRP的I B期首次人体临床试验计划于2026年正式开展。该公司已确保一项高达1亿美元的资金支持，为临床试验的顺利推进提供了坚实的财务保障。\n此次I B期试验标志着PRP在研发进程中迈出关键一步，旨在评估该药物在人体中的安全性与初步疗效。充足的资金储备将助力公司高效执行临床开发计划，加速潜在疗法的上市进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167918509","title":"Propanc Biopharma, Inc. 公布PRP在临床前胰腺癌模型中展示超过85%的肿瘤生长抑制效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1167918509","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167918509?lang=zh_cn&edition=full","pubTime":"2026-03-12 21:06","pubTimestamp":1773320779,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. 近期宣布，其研发的主要候选药物PRP在针对胰腺癌的临床前研究中取得了显著成果。数据显示，PRP能够有效抑制肿瘤生长，抑制率超过85%。这一积极结果凸显了PRP在治疗胰腺癌方面的巨大潜力，为后续的临床开发提供了强有力的科学依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192836728","title":"Propanc Biopharma与Fyonibio签署服务协议，为1B期首次人体研究建立并验证药代动力学分析方法","url":"https://stock-news.laohu8.com/highlight/detail?id=1192836728","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192836728?lang=zh_cn&edition=full","pubTime":"2026-03-10 20:45","pubTimestamp":1773146712,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. 已正式与Fyonibio达成一项服务协议，核心目标是为其即将开展的1B期首次人体临床研究，建立并验证一套关键的药代动力学分析方法。该协议的签署标志着公司在推进其领先候选药物研发进程中迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170463595","title":"Propanc Biopharma主力资产PRP在临床前胰腺癌模型中显示超过85%的肿瘤生长抑制率","url":"https://stock-news.laohu8.com/highlight/detail?id=1170463595","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170463595?lang=zh_cn&edition=full","pubTime":"2026-03-03 21:48","pubTimestamp":1772545721,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. (OTC: PPCB) 宣布，其领先研发资产PRP在针对胰腺癌的临床前研究模型中，展现出超过85%的肿瘤生长抑制效果。这一积极数据进一步验证了PRP作为潜在抗癌疗法的有效性，特别是在治疗胰腺癌这一难治性癌症领域显示出巨大潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195378168","title":"Propanc Biopharma提交招股说明书 持股股东拟转售200万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1195378168","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195378168?lang=zh_cn&edition=full","pubTime":"2025-12-30 19:08","pubTimestamp":1767092892,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. 已向美国证券交易委员会（SEC）提交招股说明书，文件显示公司一名持股股东计划公开转售所持有的200万股普通股。此次股份转售属于股东个人行为，公司本身不会从此次交易中获得任何资金。该招股说明书为二级市场流通提供了必要法律依据，意味着现有股东可能通过公开市场减持其投资头寸。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593429246","title":"Propanc Biopharma, Inc.盘中异动 急速上涨6.48%报0.693美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593429246","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593429246?lang=zh_cn&edition=full","pubTime":"2025-12-23 22:39","pubTimestamp":1766500770,"startTime":"0","endTime":"0","summary":"北京时间2025年12月23日22时39分，Propanc Biopharma, Inc.股票出现波动，股价大幅拉升6.48%。Propanc Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.25%。其相关个股中，Klotho Neurosciences Inc C/Wts 21/06/2029 、Liminatus Pharma Inc C/Wts 30/04/2030 、Celularity Inc C/Wts 16/07/2026 涨幅较大，Lexaria Bioscience Corp.、Pmgc Holdings Inc.、Reviva Pharmaceuticals Holdings, Inc.较为活跃，换手率分别为62.32%、19.47%、17.58%，振幅较大的相关个股有健永生技、Chemomab Therapeutics Ltd、Moolec Science Sa，振幅分别为22.93%、20.10%、14.61%。Propanc Biopharma, Inc.公司简介：Propanc Biopharma Inc是一家处于发展阶段的医疗保健公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223223930953b9123&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223223930953b9123&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PPCBD","PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2587998737","title":"Propanc Biopharma, Inc.盘中异动 早盘股价大涨5.23%报0.847美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2587998737","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2587998737?lang=zh_cn&edition=full","pubTime":"2025-11-28 23:38","pubTimestamp":1764344314,"startTime":"0","endTime":"0","summary":"北京时间2025年11月28日23时38分，Propanc Biopharma, Inc.股票出现波动，股价急速拉升5.23%。Propanc Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.30%。其相关个股中，Pasithea Therapeutics Corp C/Wts 12/08/2026 、Pasithea Therapeutics Corp.、Liminatus Pharma Inc C/Wts 30/04/2030 涨幅较大，Aditxt, Inc.、Pasithea Therapeutics Corp.、Cdt Equity Inc.较为活跃，换手率分别为3825.43%、1505.30%、241.69%，振幅较大的相关个股有Pasithea Therapeutics Corp C/Wts 12/08/2026 、Pasithea Therapeutics Corp.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为111.14%、67.92%、35.60%。Propanc Biopharma, Inc.公司简介：Propanc Biopharma Inc是一家处于发展阶段的医疗保健公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251128233835a717e595&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251128233835a717e595&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PPCBD","PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2583579368","title":"Propanc Biopharma, Inc.盘中异动 早盘股价大跌5.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583579368","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583579368?lang=zh_cn&edition=full","pubTime":"2025-11-14 00:09","pubTimestamp":1763050183,"startTime":"0","endTime":"0","summary":"北京时间2025年11月14日00时09分，Propanc Biopharma, Inc.股票出现波动，股价大幅下跌5.64%。Propanc Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.56%。其相关个股中，Mersana Therapeutics, Inc.、Lexaria Bioscience Corp C/Wts 14/01/2026 、Outlook Therapeutics, Inc.涨幅较大，Clearmind Medicine Inc.、Salarius Pharmaceuticals, Inc.、Outlook Therapeutics, Inc.较为活跃，换手率分别为4887.22%、407.27%、67.00%，振幅较大的相关个股有Clearmind Medicine Inc.、Outlook Therapeutics, Inc.、Osr Holdings Inc C/Wts 09/02/2028 ，振幅分别为107.67%、30.47%、29.51%。Propanc Biopharma, Inc.公司简介：Propanc Biopharma Inc是一家处于发展阶段的医疗保健公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114000944950293d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114000944950293d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PPCB","PPCBD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2582165663","title":"Propanc Biopharma, Inc.盘中异动 大幅跳水5.65%报0.851美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582165663","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582165663?lang=zh_cn&edition=full","pubTime":"2025-11-11 23:41","pubTimestamp":1762875678,"startTime":"0","endTime":"0","summary":"北京时间2025年11月11日23时41分，Propanc Biopharma, Inc.股票出现波动，股价大幅下挫5.65%。Propanc Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.79%。其相关个股中，Engene Holdings Inc C/Wts 31/10/2028  Cl A、Engene Holdings Inc.、Quoin Pharmaceuticals Ltd涨幅较大，Quoin Pharmaceuticals Ltd、Aspire Biopharma Holdings, Inc.、Salarius Pharmaceuticals, Inc.较为活跃，换手率分别为2627.31%、345.35%、282.14%，振幅较大的相关个股有Engene Holdings Inc C/Wts 31/10/2028  Cl A、Quoin Pharmaceuticals Ltd、Engene Holdings Inc.，振幅分别为72.31%、58.48%、54.91%。Propanc Biopharma, Inc.公司简介：Propanc Biopharma Inc是一家处于发展阶段的医疗保健公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511112341189762cb1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511112341189762cb1d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PPCBD","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130774186","title":"Propanc Biopharma, Inc. 进行战略收购计划，瞄准市值低于净资产价值的数字资产财政公司","url":"https://stock-news.laohu8.com/highlight/detail?id=1130774186","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130774186?lang=zh_cn&edition=full","pubTime":"2025-11-04 20:01","pubTimestamp":1762257670,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. 进行战略收购计划，瞄准市值低于净资产价值的数字资产财政公司。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139253764","title":"Propanc Biopharma与Hexstone Capital达成高达1亿美元的战略融资协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1139253764","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139253764?lang=zh_cn&edition=full","pubTime":"2025-10-15 20:45","pubTimestamp":1760532334,"startTime":"0","endTime":"0","summary":"Propanc Biopharma与Hexstone Capital达成高达1亿美元的战略融资协议","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.propanc.com","stockEarnings":[{"period":"1week","weight":-0.1304},{"period":"1month","weight":-0.0215},{"period":"3month","weight":-0.6402},{"period":"6month","weight":-0.9194},{"period":"1year","weight":-0.9656},{"period":"ytd","weight":-0.8136}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.126},{"period":"3month","weight":0.0253},{"period":"6month","weight":0.0433},{"period":"1year","weight":0.2837},{"period":"ytd","weight":0.0435}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Propanc Biopharma, Inc.最初于2007年10月15日在澳大利亚维多利亚州墨尔本成立。2010年11月23日，该公司在特拉华州重新注册并重新注册。他们是一家发展阶段的医疗保健公司，目前专注于为患有胰腺癌、卵巢癌和癌症的患者开发新的癌症治疗方法。利用他们的科学和肿瘤学顾问，他们开发了一种合理的抗癌化合物复合配方，这些化合物共同发挥多种作用，旨在控制或防止肿瘤在体内复发和扩散。他们的主要候选产品PRP是他们新配方的变体，涉及酶原，即酶的无活性前体。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.358631},{"month":2,"riseRate":0,"avgChangeRate":-0.3412},{"month":3,"riseRate":0,"avgChangeRate":-0.231595},{"month":4,"riseRate":0,"avgChangeRate":-0.398944},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.073453},{"month":6,"riseRate":0.666667,"avgChangeRate":0.742287},{"month":7,"riseRate":0.25,"avgChangeRate":-0.019906},{"month":8,"riseRate":0,"avgChangeRate":-0.482224},{"month":9,"riseRate":0,"avgChangeRate":-0.414214},{"month":10,"riseRate":0,"avgChangeRate":-0.267792},{"month":11,"riseRate":0,"avgChangeRate":-0.325477},{"month":12,"riseRate":0.25,"avgChangeRate":-0.177783}],"exchange":"NASDAQ","name":"Propanc Biopharma, Inc.","nameEN":"Propanc Biopharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Propanc Biopharma, Inc.(PPCB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Propanc Biopharma, Inc.(PPCB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Propanc Biopharma, Inc.,PPCB,Propanc Biopharma, Inc.股票,Propanc Biopharma, Inc.股票老虎,Propanc Biopharma, Inc.股票老虎国际,Propanc Biopharma, Inc.行情,Propanc Biopharma, Inc.股票行情,Propanc Biopharma, Inc.股价,Propanc Biopharma, Inc.股市,Propanc Biopharma, Inc.股票价格,Propanc Biopharma, Inc.股票交易,Propanc Biopharma, Inc.股票购买,Propanc Biopharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Propanc Biopharma, Inc.(PPCB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Propanc Biopharma, Inc.(PPCB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}